ArticleBMC complementary medicine and therapies2022
Exploring the mechanism and experimental verification of puerarin in the treatment of endometrial carcinoma based on network pharmacology and bioinformatics analysis.
Article in BMC complementary medicine and therapies, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 41 citations in OpenAlex.
- Recent advances in characterizing the immune microenvironment and biomarkers of endometrial carcinoma.Frontiers in immunology · 2026Review
- An MRI-based radiomics nomogram to predict progression-free survival in patients with endometrial cancer.Future oncology (London, England) · 2025Article
- Development and validation of an immune-related gene signature for the prognostic and immune landscape prediction in head and neck squamous cell carcinoma by integrated analysis of machine learning and Mendelian randomization.Translational cancer research · 2025Article
- Pancancer Analysis of NSUN2 with a Focus on Prognostic and Immunological Roles in Endometrial Cancer.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Single-cell insights into HNSCC tumor heterogeneity and programmed cell death pathways.Translational oncology · 2025Article
- Discovering the Potential Role of the C2 DUSP2+ MCs Subgroup in Lung Adenocarcinoma.Translational oncology · 2025Article
- Prognostic implications of ERLncRNAs in ccRCC: a novel risk score model and its association with tumor mutation burden and immune microenvironment.Discover oncology · 2025Article
- MAZ-mediated tumor progression and immune evasion in hormone receptor-positive breast cancer: Targeting tumor microenvironment and PCLAF+ subtype-specific therapy.Translational oncology · 2025Article
- Heterogeneity of cancer-associated fibroblast subpopulations in prostate cancer: Implications for prognosis and immunotherapy.Translational oncology · 2025Article
- Decoding multiple myeloma: single-cell insights into tumor heterogeneity, immune dynamics, and disease progression.Frontiers in immunology · 2025Article
- Integrative single-cell and spatial transcriptomics uncover ELK4-mediated mechanisms inFrontiers in immunology · 2025Article
- Dissecting the endothelial cell landscape in meningioma: single-cell insights intoFrontiers in immunology · 2025Article
- Decoding neuroinflammation in Alzheimer's disease: a multi-omics and AI-driven perspective for precision medicine.Frontiers in immunology · 2025Review
- Integrated multi-omics analysis reveals the immunotherapeutic significance of tumor cells with high FN1 expression in ovarian cancer.Frontiers in molecular biosciences · 2025Article
- Single-cell technologies and spatial transcriptomics: decoding immune low - response states in endometrial cancer.Frontiers in immunology · 2025Review
- Mapping the immunological landscape and emerging immunotherapeutic strategies in cervical cancer: a comprehensive review.Frontiers in oncology · 2025Review
- Single-cell and spatial atlas of glioblastoma heterogeneity: characterizing theFrontiers in immunology · 2025Article
- Identification of necroptosis-related gene signatures for predicting the prognosis of ovarian cancer.Scientific reports · 2024Article
- Combining bulk and scRNA-seq to explore the molecular mechanisms governing the distinct efferocytosis activities of a macrophage subpopulation in PDAC.Journal of cellular and molecular medicine · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial carcinoma is one of the two cancers with rising mortality and morbidity in recent years. In the light of many controversies about its treatment, it is urgent to construct a new prognostic model and to find out new therapeutic directions. As a small drug molecule widely used in clinical treatment and experimental research in China, puerarin has recently been proven to have obvious anti-cancer effects in multiple cancer cells. In this study, bioinformatics analysis and experimental validation were used to explore the potential mechanism of puerarin for endometrial carcinoma and construct a prognostic model. A total of 22 drug-related differential genes were found by constructing a database of drug targets and disease genes. The protein-protein interaction network was constructed for GO and KEGG enrichment analysis to initially explore the potential mechanism of its therapeutic effects. To construct the prognostic model, validation was performed by risk regression analysis and LASSO analysis. Finally, two prognostic genes-PIM1 and BIRC5 were determined to establish high and low risk groups. Kaplan-Meier analysis displayed a higher survival rate in the low-risk group than in the high-risk group. ROC curves indicated the stable and good effect in prediction (one-year AUC is 0.626; two-year AUC is 0.620; three-year AUC is 0.623). The interrelationship between immunity and its disease was explored by immune infiltration analysis. Finally, the potential effect of puerarin on endometrial carcinoma cells was further verified by experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.